Findings

What do systematic reviews say?

4 questions · 4 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 25%Moderate 3 · 75%High 0 · 0%

Anti‐CTLA4 monoclonal antibodies plus chemotherapy vs chemotherapy alone

Progression‐free survival · people with cutaneous melanoma

Anti‐CTLA4 monoclonal antibodies plus chemotherapy probably leads to lower progression‐free survival† compared with chemotherapy (moderate certainty).

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
HR 0.76 [0.63, 0.92]
502 participants
Moderate

Anti‐CTLA4 monoclonal antibodies plus chemotherapy vs chemotherapy alone

Tumour response · people with cutaneous melanoma

Anti‐CTLA4 monoclonal antibodies plus chemotherapy showed no clear difference in tumour response compared with chemotherapy (moderate certainty).

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
RR 1.28 [0.92, 1.77]
1157 participants
Moderate

Anti‐CTLA4 monoclonal antibodies plus chemotherapy vs chemotherapy alone

Toxicity (≥ G3) · people with cutaneous melanoma

Anti‐CTLA4 monoclonal antibodies plus chemotherapy probably leads to higher toxicity (≥ G3) compared with chemotherapy (moderate certainty).

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
RR 1.69 [1.19, 2.42]
1142 participants
Moderate

Anti‐CTLA4 monoclonal antibodies plus chemotherapy vs chemotherapy alone

Overall survival† · people with cutaneous melanoma

Anti‐CTLA4 monoclonal antibodies plus chemotherapy showed no clear difference in overall survival† compared with chemotherapy (low certainty).

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
HR 0.81 [0.65, 1.01]
1157 participants
Low